Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study.


Journal

European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 21 03 2019
accepted: 14 10 2019
revised: 10 10 2019
pubmed: 16 11 2019
medline: 20 11 2020
entrez: 16 11 2019
Statut: ppublish

Résumé

Relapses of steroid-sensitive nephrotic syndrome are traditionally treated with prednisone 2 mg/kg/day or 60 mg/m

Identifiants

pubmed: 31728673
doi: 10.1007/s00431-019-03506-5
pii: 10.1007/s00431-019-03506-5
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Prednisone VB0R961HZT

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

279-283

Références

Buchman AL (2001) Side effects of corticosteroid therapy. J Clin Gastroenterol 33:289–294
doi: 10.1097/00004836-200110000-00006
Deschênes G, Vivarelli M, Peruzzi L, ESPN Working Group on Idiopathic Nephrotic Syndrome (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647–654. https://doi.org/10.1007/s00431-017-2891-2892
doi: 10.1007/s00431-017-2891-2892 pubmed: 28303389
Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639
doi: 10.1016/S0140-6736(03)14184-0
Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA (2009) Management of childhood onset nephrotic syndrome. Pediatrics 124:747–757. https://doi.org/10.1542/peds.2008-1559
doi: 10.1542/peds.2008-1559 pubmed: 19651590
Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28:415–426. https://doi.org/10.1007/s00467-012-2310-x
doi: 10.1007/s00467-012-2310-x pubmed: 23052651
Mehls O, Hoyer PF (2011) Dosing of glucocorticosteroids in nephrotic syndrome. Pediatr Nephrol 26:2095–2098. https://doi.org/10.1007/s00467-011-1993-8
doi: 10.1007/s00467-011-1993-8 pubmed: 21904778
Mishra OP, Basu B, Upadhyay SK, Prasad R, Schaefer F (2010) Behavioural abnormalities in children with nephrotic syndrome. Nephrol Dial Transplant 25:2537–2541. https://doi.org/10.1093/ndt/gfq097
doi: 10.1093/ndt/gfq097 pubmed: 20200003
Pasini A, Aceto G, Ammenti A, NefroKid Study Group et al (2015) Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr Nephrol 30:91–101. https://doi.org/10.1007/s00467-014-2903-7
doi: 10.1007/s00467-014-2903-7 pubmed: 25127916
Raja K, Parikh A, Webb H, Hothi D (2017) Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol 32:99–105
doi: 10.1007/s00467-016-3458-6
Raman V, Krishnamurthy S, Harichandrakumar KT (2016) Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial. Pediatr Nephrol 31:595–604. https://doi.org/10.1007/s00467-015-3285-1
doi: 10.1007/s00467-015-3285-1 pubmed: 26759000
Samuel S, Morgan CJ, Bitzan M, Mammen C, Dart AB, Manns BJ, Alexander RT, Erickson RL, Grisaru S, Wade AW, Blydt-Hansen T, Feber J, Arora S, Licht C, Zappitelli M (2013) Substantial practice variation exists in the management of childhood nephrotic syndrome. Pediatr Nephrol 28:2289–2298. https://doi.org/10.1007/s00467-013-2546-0
doi: 10.1007/s00467-013-2546-0 pubmed: 23917450
Tarshis P, Tobin JN, Bernstein J, Edelman CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the international study of kidney disease in children. J Am Soc Nephrol 8:769–776

Auteurs

Yael Borovitz (Y)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.

Hadas Alfandary (H)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Orly Haskin (O)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.

Shely Levi (S)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shulamit Kaz (S)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.

Miriam Davidovits (M)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amit Dagan (A)

Institute of Nephrology, Schneider Children's Medical Center of Israel, 4920235, Petach Tikva, Israel. dagana@clalit.org.il.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. dagana@clalit.org.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH